> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Rejects All Mid-Link Technology Data
- URL: https://www.fdaweb.com/fda-rejects-all-mid-link-technology-data/
- Published: 2025-03-11T12:00:00.000Z
- Updated: 2026-09-14T14:55:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158799

FDA says it is rejecting all study data from all studies conducted at Mid-Link Technology Testing Co. in Tianjin, China, until the firm demonstrates that the issues described in the agency’s 12/30/2024 general correspondence letter (GCL) have been adequately addressed. The agency announced the move in a 2/26 [letter](fda.gov/media/185743/download?attachment) citing the GCL and the company’s inadequate response dated 1/29.

The latest FDA letter reiterates its position that Mid-Link copied the results of another study or created falsified or otherwise invalid data that was submitted to FDA. It says the firm’s response did not resolve agency data integrity concerns about the data generated by the firm, including the cause of significant data anomalies present in its studies.

FDA says an adequate response may include, among other things, the firm’s documentation of its implementation and following of procedures that are sufficient to prevent the use of copied or otherwise falsified or invalid data. The letter acknowledges the firm’s request for a meeting with agency officials and says such a meeting would not be beneficial at this time because of the lack of a substantive response to the issues in the GCL.